Eli Lilly and Company

Qynapse Further Strengthens its Executive Leadership Team with the Appointment of Adam Schwarz, Ph.D., as Chief Scientific Officer

Thursday, October 21, 2021 - 2:00pm

BOSTON, Oct. 21, 2021 /PRNewswire/ -- Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, announced today the appointment of Adam J. Schwarz, Ph.D., as Chief Scientific Officer (CSO).

Key Points: 
  • BOSTON, Oct. 21, 2021 /PRNewswire/ -- Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, announced today the appointment of Adam J. Schwarz, Ph.D., as Chief Scientific Officer (CSO).
  • In his new role, Dr. Schwarz is responsible for envisioning and developing Qynapse's scientific research strategies and operations, and for expanding and communicating their product offering and scientific validation with the scientific and customer communities.
  • Dr. Schwarz has an active scientific profile and has authored over a hundred peer-reviewed articles, two books and several invited book chapters.
  • Qynapse is headquartered in France, in the United States and in Canada.

Cancer Immunotherapy Market - Global Forecast up to 2026: Focus on Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors, Immunomodulators - ResearchAndMarkets.com

Thursday, October 21, 2021 - 10:36am

The "Cancer Immunotherapy Market by Product Type, Application, End Users, and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Immunotherapy Market by Product Type, Application, End Users, and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Cancer Immunotherapy Market is projected to grow at the rate of 9.7% CAGR by 2026.
  • Immunotherapy is a type of treatment to cure cancer that utilizes a few parts of a person's immune system to fight cancer.
  • With the considerable pressure of increasing cancer cases and the side effects of other therapies, cancer immunotherapy has exhibited tremendous potential over the past few years.

ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

Wednesday, October 20, 2021 - 1:00pm

ShouTi Inc. , a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced computational and structure-based technology, today announced the close of a $100 million Series B financing led by BVF Partners L.P. (BVF).

Key Points: 
  • ShouTi Inc. , a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced computational and structure-based technology, today announced the close of a $100 million Series B financing led by BVF Partners L.P. (BVF).
  • Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.
  • With the completion of the Series B financing, ShouTi has raised $158 million since initiating operations.
  • Joining Dr. Stevens are:
    SVB Leerink acted as exclusive financial advisor for ShouTis Series B financing.

Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer

Wednesday, October 20, 2021 - 12:00pm

"Dr. Jansen has made significant contributions to Elevation Oncology's vision since her arrival at the Company earlier this year and we are thrilled to have her take on this role within the Elevation Oncology executive team," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology.

Key Points: 
  • "Dr. Jansen has made significant contributions to Elevation Oncology's vision since her arrival at the Company earlier this year and we are thrilled to have her take on this role within the Elevation Oncology executive team," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology.
  • "Valerie has an extensive background in oncology and a deep understanding of precision medicine, and under her leadership, Elevation Oncology is well positioned for success.
  • Prior to joining Elevation Oncology, Dr. Jansen served as Executive Medical Director at Mersana Therapeutics, a clinical-stage biopharmaceutical company with a focus in oncology, where she led clinical development of antibody-drug conjugate therapies for patients living with cancer.
  • She completed residency in Internal Medicine and fellowship in Medical Oncology through the ABIM Physician-Scientist Research Pathway at Vanderbilt.

OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)

Friday, October 15, 2021 - 12:03pm

Canadians living with PAH, a rare disease for which there is no cure, now have a new treatment option.

Key Points: 
  • Canadians living with PAH, a rare disease for which there is no cure, now have a new treatment option.
  • OPSYNVIshould be used in patients who are currently treated concomitantly with stable doses of macitentan 10mg and tadalafil 40mg (20mg x 2) as separate tablets.
  • If left untreated, PH can lead to right ventricle failure, a serious type of heart failure.
  • As a combination therapy, OPSYNVI conveniently offers two therapies in one daily pill simplifying treatment for patients."

Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer

Thursday, October 14, 2021 - 3:45pm

A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.

Key Points: 
  • A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
  • In-depth interviews were conducted with 12 of the world's foremost KOLs in the United States and Europe.
  • How do KOLs assess Turning Point's pipeline repotrectinib and AnHeart's taletrectinib in the treatment of ROS1-positive NSCLC?
  • Why do KOLs expect Eli Lilly's late-stage Retevmo/Retsevmo and Blueprint Medicines/Roche's Gavreto will become front-line treatments for RET-fusion positive NSCLC?

BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies

Thursday, October 14, 2021 - 9:00am

Scientists deployed BenevolentAI's powerful target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature or patents linking the gene to ulcerative colitis.

Key Points: 
  • Scientists deployed BenevolentAI's powerful target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature or patents linking the gene to ulcerative colitis.
  • BenevolentAI used its advanced molecular design capabilities to generate a potential best-in-class, oral, peripherally restricted candidate drug within two years of target validation.
  • The preclinical candidate has been experimentally validated in ex-vivo ulcerative colitis colon samples from patients who were unresponsive to the standard of care treatment.
  • Joanna Shields, Chief Executive Officer of BenevolentAI, commented, "Nominating a drug candidate for a novel ulcerative colitis target identified by our AI-drug discovery platform represents a milestone for BenevolentAI but more importantly, advances a new potential treatment for this debilitating disease."

BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies

Thursday, October 14, 2021 - 9:00am

LONDON, Oct. 14, 2021 /PRNewswire/ -- In a significant milestone for its (AI)-driven drug discovery platform, BenevolentAI has nominated a preclinical candidate for a novel ulcerative colitis target, and plans to advance the asset into clinical trials.

Key Points: 
  • Scientists deployed BenevolentAI's powerful target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature or patents linking the gene to ulcerative colitis.
  • BenevolentAI used its advanced molecular design capabilities to generate a potential best-in-class, oral, peripherally restricted candidate drug within two years of target validation.
  • The preclinical candidate has been experimentally validated in ex-vivo ulcerative colitis colon samples from patients who were unresponsive to the standard of care treatment.
  • Joanna Shields, Chief Executive Officer of BenevolentAI, commented, "Nominating a drug candidate for a novel ulcerative colitis target identified by our AI-drug discovery platform represents a milestone for BenevolentAI but more importantly, advances a new potential treatment for this debilitating disease."

Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

Thursday, October 14, 2021 - 6:30am

BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.

Key Points: 
  • BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.
  • For more information on BC Lispro, visit our website: https://www.adocia.com/products/biochaperone-ultra-fast-analog-insulin/
    Adocias partner Tonghua Dongbao is one of the leading insulin providers in Asia.
  • In 2018, Adocia and partner Tonghua Dongbao signed a strategic alliance to develop and commercialize BC Lispro in China and other Asian territories.
  • Tonghua Dongbao also supplies insulin lispro and insulin glargine to Adocia for the worldwide market, except China.

Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

Thursday, October 14, 2021 - 6:30am

BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.

Key Points: 
  • BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.
  • For more information on BC Lispro, visit our website: https://www.adocia.com/products/biochaperone-ultra-fast-analog-insulin/
    Adocias partner Tonghua Dongbao is one of leading insulin providers in Asia.
  • In 2018, Adocia and partner Tonghua Dongbao signed a strategic alliance to develop and commercialize BC Lispro in China and other Asian territories.
  • Tonghua Dongbao also supplies insulin lispro and insulin glargine to Adocia for the worldwide market, except China.